TY - JOUR
T1 - IgG antibody prevalence suggests high immunization needs in newcomers to Luxembourg, 2012
AU - Hübschen, Judith M.
AU - Charpentier, Emilie
AU - Weicherding, Pierre
AU - Muller, Claude P.
N1 - Funding Information:
This work was financially supported by the Grand Duchy of Luxembourg through the Ministries of Health and of Higher Education and Research and the Laboratoire National de Sant?. Dr. Weicherding from the Luxembourg Ministry of Health was involved in study design and in collection of data and agreed to the submission of the article for publication. None of the other funding sources had any involvement in study design, collection, analysis and interpretation of data, writing of the report or the decision to submit the article for publication.
Funding Information:
This work was financially supported by the Grand Duchy of Luxembourg through the Ministries of Health and of Higher Education and Research and the Laboratoire National de Santé . Dr. Weicherding from the Luxembourg Ministry of Health was involved in study design and in collection of data and agreed to the submission of the article for publication. None of the other funding sources had any involvement in study design, collection, analysis and interpretation of data, writing of the report or the decision to submit the article for publication.
Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Vaccine coverage of the general population in Luxembourg is high, but refugees or asylum seekers may be incompletely vaccinated and susceptible to vaccine-preventable diseases. In order to assess protection rates, serum and oral fluid samples were collected from 406 newcomers aged between 13 and 70 years arriving between May and September 2012. Sera were screened for IgG antibodies against measles, rubella, mumps, hepatitis B, tetanus, diphtheria and pertussis. Oral fluid samples were screened for antibodies against measles, mumps and rubella virus to investigate their suitability for antibody prevalence studies. More than 90% of the participants had IgG antibodies against rubella, 73% against measles and 56% against mumps. Less than 19% had anti-HBs antibodies. Nearly 84% of the participants had an adequate protection against tetanus, 73% against diphtheria and 40% had pertussis antibodies. 93%, 95% and 78% of the measles, rubella and mumps test results obtained with serum and oral fluid were concordant. The majority of the participants lacked antibodies against at least one of the measles/mumps/rubella (58%) and diphtheria/tetanus/pertussis (72%) vaccine components and against hepatitis B virus (82%) and might thus profit from vaccination. Oral fluid is a suitable alternative and non-invasive specimen for measles/rubella antibody prevalence studies.
AB - Vaccine coverage of the general population in Luxembourg is high, but refugees or asylum seekers may be incompletely vaccinated and susceptible to vaccine-preventable diseases. In order to assess protection rates, serum and oral fluid samples were collected from 406 newcomers aged between 13 and 70 years arriving between May and September 2012. Sera were screened for IgG antibodies against measles, rubella, mumps, hepatitis B, tetanus, diphtheria and pertussis. Oral fluid samples were screened for antibodies against measles, mumps and rubella virus to investigate their suitability for antibody prevalence studies. More than 90% of the participants had IgG antibodies against rubella, 73% against measles and 56% against mumps. Less than 19% had anti-HBs antibodies. Nearly 84% of the participants had an adequate protection against tetanus, 73% against diphtheria and 40% had pertussis antibodies. 93%, 95% and 78% of the measles, rubella and mumps test results obtained with serum and oral fluid were concordant. The majority of the participants lacked antibodies against at least one of the measles/mumps/rubella (58%) and diphtheria/tetanus/pertussis (72%) vaccine components and against hepatitis B virus (82%) and might thus profit from vaccination. Oral fluid is a suitable alternative and non-invasive specimen for measles/rubella antibody prevalence studies.
KW - Diphtheria-tetanus-pertussis vaccine
KW - Hepatitis B
KW - Hepatitis C
KW - Measles-mumps-rubella vaccine
KW - Vaccine-preventable diseases
UR - http://www.scopus.com/inward/record.url?scp=85039866441&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2017.12.041
DO - 10.1016/j.vaccine.2017.12.041
M3 - Article
C2 - 29306505
AN - SCOPUS:85039866441
SN - 0264-410X
VL - 36
SP - 899
EP - 905
JO - Vaccine
JF - Vaccine
IS - 6
ER -